Connect with us

Health

PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan – Medscape

Sacubitril valsartan (Entresto), deemed ‘the Big E’ by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific…

Published

on

Article feature image

The PARADISE-MI trial comparing sacubitril/valsartan to ramipril in patients with left ventricular dysfunction after myocardial infarction (MI) and clinical heart failure led off the late-breaking clinical trial session at the American College of Cardiology (ACC) 2021 Scientific Session. Organizers tend to reserve this slot for the biggest newsmakers.
And if the angiotensin neprilysin inhibitor had been associated with a statistically significant reduction of the primary endpoint of cardiovascular…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending